Clarisonic Debuts Anti-Aging System, Making Good On Innovation Promise

Clarisonic announced plans in late 2016 to outsource device manufacturing and focus on innovation, and the brand figures in parent L’Oreal’s vision for a “comeback” in skin care. The newly launched Clarisonic Smart Profile Uplift system combines core cleansing technology with a specialized Firming Massage Head for benefits across 15 signs of aging, the company says.

L’Oreal S.A.’s Clarisonic unit extends its sonic cleansing technology into anti-aging skin care with new Smart Profile Uplift, available now on the brand’s website and headed to Sephora.com in mid-March.

Described as a “2-in1 cleansing and micro-firming face massage device,” the new addition to Clarisonic’s portfolio features “a unique sonic...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Archive

Non-US Approvals - Clone

Devices authorized for marketing outside the US. Data derived from Citeline’s Meddevicetracker. Updated weekly.

Patient access to unapproved medical products allowed under DeFazio, Daschle bills.

 
• By 

PATIENT ACCESS TO UNAPPROVED MEDICAL PRODUCTS WOULD BE ALLOWED under legislation introduced by Rep. Peter DeFazio (D-Ore.) on July 12 and Sen. Tom Daschle (D-S.D.) on July 14. Called the Access to Medical Treatment Act, the legislation would allow health practitioners to administer unapproved drugs, devices, foods or dietary supplements to patients as long as there is no evidence the treatment causes harm and the patient is informed about the treatment and its possible side effects. DeFazio's bill is identified as HR 2019; Daschle's version will be assigned a bill number the week of July 17.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

More from HBW Insight

data

Type:DataArticle | Publication:HBW | Section:Health | Paywall:Premium — Article containing all Composer content for testing (Do not update)

 
• By 

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.

Test: PDF Link Lifetime

Description description

headline test

description